TW201138766A - Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof - Google Patents

Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof Download PDF

Info

Publication number
TW201138766A
TW201138766A TW099138227A TW99138227A TW201138766A TW 201138766 A TW201138766 A TW 201138766A TW 099138227 A TW099138227 A TW 099138227A TW 99138227 A TW99138227 A TW 99138227A TW 201138766 A TW201138766 A TW 201138766A
Authority
TW
Taiwan
Prior art keywords
group
composition
doc
carboxylic acid
sodium
Prior art date
Application number
TW099138227A
Other languages
English (en)
Chinese (zh)
Inventor
Robert M Burk
Wha Bin Im
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43503864&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW201138766(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of TW201138766A publication Critical patent/TW201138766A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW099138227A 2009-12-09 2010-11-05 Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof TW201138766A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26789709P 2009-12-09 2009-12-09

Publications (1)

Publication Number Publication Date
TW201138766A true TW201138766A (en) 2011-11-16

Family

ID=43503864

Family Applications (1)

Application Number Title Priority Date Filing Date
TW099138227A TW201138766A (en) 2009-12-09 2010-11-05 Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof

Country Status (16)

Country Link
US (2) US20110136872A1 (cg-RX-API-DMAC7.html)
EP (1) EP2509582A1 (cg-RX-API-DMAC7.html)
JP (2) JP5955774B2 (cg-RX-API-DMAC7.html)
KR (1) KR20120106788A (cg-RX-API-DMAC7.html)
CN (1) CN102762195B (cg-RX-API-DMAC7.html)
AR (1) AR078929A1 (cg-RX-API-DMAC7.html)
AU (1) AU2010328555B2 (cg-RX-API-DMAC7.html)
CA (1) CA2783707A1 (cg-RX-API-DMAC7.html)
CL (1) CL2012001545A1 (cg-RX-API-DMAC7.html)
IL (1) IL220240A0 (cg-RX-API-DMAC7.html)
MX (1) MX2012006622A (cg-RX-API-DMAC7.html)
NZ (1) NZ600577A (cg-RX-API-DMAC7.html)
RU (1) RU2012127869A (cg-RX-API-DMAC7.html)
SG (1) SG181600A1 (cg-RX-API-DMAC7.html)
TW (1) TW201138766A (cg-RX-API-DMAC7.html)
WO (1) WO2011071620A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2711425T3 (es) 2012-08-27 2019-05-03 Allergan Inc Espesamiento de la córnea central reducido mediante el uso de profármacos de éster hidrófilos de beta-clorociclopentanos
KR101535825B1 (ko) 2012-09-25 2015-07-10 엘지디스플레이 주식회사 표시장치 및 이의 라인결함 검출방법
CN106029643A (zh) * 2014-02-20 2016-10-12 阿勒根公司 通过使用β-氯环戊烷的亲水性酯前药减少中心角膜增厚
ES2757798T3 (es) 2014-10-02 2020-04-30 Allergan Inc Profármacos de éster de gamma-lactamas y su uso

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028624A (en) * 1989-07-27 1991-07-02 Allergan, Inc. Intraocular pressure reducing 9,15-diacyl prostaglandins
US5034413A (en) 1989-07-27 1991-07-23 Allergan, Inc. Intraocular pressure reducing 9,11-diacyl prostaglandins
CA2021316C (en) * 1989-07-27 2000-10-24 Ming Fai Chan Intraocular pressure reducing 11-acyl prostaglandins
US4994274A (en) * 1989-07-27 1991-02-19 Allergan, Inc. Intraocular pressure reducing 11,15-diacyl prostaglandins and method of using
WO2000004898A1 (en) * 1998-07-21 2000-02-03 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
KR100854056B1 (ko) * 2000-09-13 2008-08-26 산텐 세이야꾸 가부시키가이샤 점안액
ES2294361T3 (es) * 2002-08-23 2008-04-01 Santen Pharmaceutical Co., Ltd. Colirios estables que contienen latanoprost como principio activo.
WO2005115401A1 (es) * 2004-05-26 2005-12-08 Arturo Jimenez Bayardo Un método para preparar una solución oftálmica de latanoprost y solución resultante
US20050276867A1 (en) * 2004-06-09 2005-12-15 Allergan, Inc. Stabilized compositions comprising a therapeutically active agent and an oxidizing preservative
PL1856042T3 (pl) * 2005-03-10 2012-11-30 Allergan Inc Podstawione gamma laktamy jako środki terapeutyczne
US20100120908A1 (en) * 2007-02-07 2010-05-13 Teika Pharmaceutical Co., Ltd Eye drop preparation comprising latanoprost
CN102076681A (zh) * 2008-04-24 2011-05-25 阿勒根公司 作为治疗剂的取代γ-内酰胺
EP2127638A1 (en) * 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma

Also Published As

Publication number Publication date
IL220240A0 (en) 2012-07-31
JP2013513606A (ja) 2013-04-22
RU2012127869A (ru) 2014-01-20
KR20120106788A (ko) 2012-09-26
WO2011071620A1 (en) 2011-06-16
CL2012001545A1 (es) 2012-08-31
US20160220677A1 (en) 2016-08-04
US20110136872A1 (en) 2011-06-09
NZ600577A (en) 2014-10-31
AU2010328555B2 (en) 2016-05-26
CN102762195A (zh) 2012-10-31
AU2010328555A1 (en) 2012-07-05
JP5955774B2 (ja) 2016-07-20
JP2016056207A (ja) 2016-04-21
CN102762195B (zh) 2016-05-18
SG181600A1 (en) 2012-07-30
AR078929A1 (es) 2011-12-14
CA2783707A1 (en) 2011-06-16
EP2509582A1 (en) 2012-10-17
MX2012006622A (es) 2012-08-15

Similar Documents

Publication Publication Date Title
US10894043B2 (en) Pharmaceutical composition
US8637054B2 (en) Polymeric delivery system for a nonviscous prostaglandin-based solution without preservatives
CN100391461C (zh) 降血压性脂质和噻吗洛尔组合物及其使用的方法
US8299124B2 (en) Aqueous intraocular penetration-promoting eye drop
JP2019108377A (ja) フッ化インテグリンアンタゴニスト
JP2018510139A (ja) フッ化テトラヒドロナフチリジニルノナン酸誘導体およびその使用法
CN103747786A (zh) 比马前列素和溴莫尼定的固定剂量组合
TW201204366A (en) Ophthalmic composition for treating retinal disease
WO2017002941A1 (ja) クエン酸エステルを含有するデポ剤
TW201138766A (en) Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof
RU2672057C2 (ru) Ингибитор хориоретинальных нарушений
KR20170088875A (ko) 수술 후 안구 염증성 병태를 억제시키기 위한 전방내용의, 항―염증성 및 산동성 용액
TWI336701B (en) Compositions and methods for treating or preventing glaucoma or progression thereof
TW200946113A (en) PAI-1 expression and activity inhibitors for the treatment of ocular disorders
JP2009519962A (ja) 眼投与用局所メカミルアミン製剤およびその使用
JP2005047909A (ja) ピペリジン誘導体を有効成分とする掻痒治療剤
BRPI0615245A2 (pt) agonistas de receptor ep2 para tratamento de glaucoma
WO2010056710A1 (en) Compositions and methods for treating eye diseases
TWI677346B (zh) 含有多肽之醫藥組成物
JP2009235069A (ja) ３’，５−ジ−２−プロペニル−（１，１’−ビフェニル）−２，４’−ジオールを有効成分として含有する視神経障害の予防又は治療剤
WO2023176720A1 (ja) 網膜血管拡張剤及び医薬組成物
JP2020059652A (ja) タフルプロストとクエン酸エステルとを含有するデポ剤
HK1070830B (en) Hypotensive lipid and timolol compositions and methods of using same